Study of IBI323 in Patients With Advanced Malignancies

Advanced Malignancies Clinical Trial

Official title:

A Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of IBI323 in Participants With Advanced Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04916119
• Other study ID #: CIBI323A101
• Status: Recruiting
• Phase: Phase 1
• Start date: June 29, 2021
• Est. completion date: December 9, 2023

Study information

• Verified date: September 2022
• Source: Innovent Biologics (Suzhou) Co. Ltd.
• Contact: yu Wang
• Phone: 0512-69566088
• Email: yu.wang01[@]innoventbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate safety, tolerability and efficacy of IBI323(anti-LAG-3/PD-L1) or in combination with chemotherapy in participants with advanced malignancies. Another purpose is to determine the pharmacokinetics,pharmacodynamics and immunogenicity of IBI323

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 322
• Est. completion date: December 9, 2023
• Est. primary completion date: June 23, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Phase Ia Patients with locally advanced, recurrent or metastatic solid tumors who have failed standard treatment Phase Ib cohort A Patients with IO-refractory advanced NSCLC cohort B Patients with IO-naive advanced NSCLC who have failed standard treatment cohort C Patients with advanced NSCLC who have no prior treatment and PD-L1 TPS=1% cohort D Patients with ES-SCLC or G3 neuroendocrine tumors who have failed standard treatment cohort E Patients with advanced MPM who have failed standard treatment cohort F Patients with advanced UC who have failed standard treatment cohort G Patients with advanced nccRCC who have failed standard treatment cohort H Patients with advanced HCC who have failed standard treatment cohort I Patients with advanced NPC who have failed standard treatment cohort J Patients with advanced CC or HNSCC who have failed standard treatment cohort K Patients with advanced GC or GEJC with HER2 negative who have no prior treatment cohort L Patients with advanced TNBC who have failed standard treatment

2. Able to understand and willing to sign the ICF.

3. 18 to 75 years old.

4. Life expectancy at least 12 weeks.

5. At least 1 measurable lesion per RECIST v1.1.

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

7. Adequate organ and bone marrow functionAdequate organ and bone marrow function.

Exclusion Criteria:

1. Prior treatment with any anti- LAG-3 antibody.

2. Prior immunotherapy treatment for Stage Ia extension cohort ( immunotherapy untreated) and Stage Ib cohort B-L

3. Any investigational drugs received within 4 weeks prior to the first study treatment.

4. Receive the last dose of anti-tumor therapy within 4 weeks before the first dose of study therapy.

5. Symptomatic CNS metastasis.

6. History of autoimmune disease , present active autoimmune disease or inflammatory diseases

7. Pregnant or nursing females.

Related Conditions & MeSH terms

• Advanced Malignancies
• Neoplasms

Intervention

Drug:
• IBI323
In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K

Locations

Country	Name	City	State
China	Shang Hai Pulmonary Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Innovent Biologics (Suzhou) Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events (AEs)	To evaluate the safety and tolerability of IBI323 [Adverse events (AEs), treatment-related AE (TRAE), immune-related AEs (irAE), serious adverse event (SAE), dose-limiting toxicity (DLT) assessed by CTCAE v5.0]	24 months
Secondary	Investigator Assessments of Overall Response Rate(ORR)	RECIST v1.1 will be used to determine ORR by investigator	24 months
Secondary	Disease Control Rate(DCR)	RECIST v1.1 will be used to determine DCR by investigator	24 months
Secondary	PFS (progression-free survival)	RECIST v1.1 will be used to determine PFS by investigator	24 months
Secondary	Anti-drug antibody (ADA)		24 months